← Back to Search

ACE inhibitor/ARB

Continuation of ACEi and/or ARBs for Chronic Kidney Disease

Waitlist Available
Led By Raymond Hsu, MD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Screening 3 weeks
Treatment Varies
Follow Up months 1-12
Awards & highlights

Study Summary

This trialseeks to determine the safety & feasibility of ACEi/ARB use for advanced CKD. Current guidelines lack evidence to support benefit of use in this group.

Eligible Conditions
  • Chronic Kidney Disease
  • High Blood Pressure
  • ACE Inhibitors
  • Angiotensin Receptor Blockers


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~months 1-12
This trial's timeline: 3 weeks for screening, Varies for treatment, and months 1-12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of all cause emergency room visits
Number of all-cause hospitalizations
Number of falls and syncope reported by patients and/or discharge summaries
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ACEi/ARB continuationExperimental Treatment1 Intervention
Intervention group will continue or start to take ACEi and/or ARBs
Group II: ACEi/ARB withdrawalActive Control1 Intervention
The control group will discontinue ACEi and/or ARBs which may be substituted with other anti-hypertensive agents (if already taking ACEi/ARB) or continue to not take ACEi/ARBs

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,500 Previous Clinical Trials
15,236,471 Total Patients Enrolled
Raymond Hsu, MDPrincipal InvestigatorUniversity of California, San Francisco
Elaine Ku, MDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
20 Total Patients Enrolled

Media Library

Continuation of ACEi and/or ARBs (ACE inhibitor/ARB) Clinical Trial Eligibility Overview. Trial Name: NCT03957161 — N/A
Chronic Kidney Disease Research Study Groups: ACEi/ARB continuation, ACEi/ARB withdrawal
Chronic Kidney Disease Clinical Trial 2023: Continuation of ACEi and/or ARBs Highlights & Side Effects. Trial Name: NCT03957161 — N/A
Continuation of ACEi and/or ARBs (ACE inhibitor/ARB) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03957161 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are recruitment efforts underway for this trial?

"Clinicaltrials.gov affirms that this medical trial, which was first posted on September 7th 2023 and last updated on October 31st 2022, is not presently enrolling participants. However, 600 other trials are open to candidates at present."

Answered by AI
~0 spots leftby Apr 2025